EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In vitro and in vivo anticancer potential of Artemisia species: Current evidence and translational challenges

Erwin Loots, Frank Van der Kooy

PhytoPharm: International Journal of Phytomedicine and Pharmacology · 02.07.2026 · 1 (1) · 100005

DOI: 10.67623/78jr1f43 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PhytoPharm: International Journal of Phytomedicine and Pharmacology, online erschienen am 02.07.2026. Verfasst von Erwin Loots und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer remains a major global health challenge, with ∼20 million new cases and 9.7 million deaths reported in 2022. Limitations of conventional chemotherapy—including systemic toxicity, multidrug resistance, and modest survival gains—continue to drive the search for novel, multi-targeted agents. This review systematically evaluates the preclinical anticancer potential of selected species within the genus Artemisia (Asteraceae), a rich source of sesquiterpene lactones, flavonoids, coumarins, and phenolic acids. In vitro data demonstrate that several extracts and fractions meet the US NCI criteria for “highly active” cytotoxicity (IC50 < 10 μg/mL), most notably ethanolic extracts of A. annua (IC50 1.38 μg/mL against melanoma), non-polar fractions of A. afra (IC50 4.5–4.7 μg/mL against triple-negative breast cancer), and methanolic extracts of A. asiatica and A. japonica (IC50 2.85–6.89 μg/mL). Bioassay-guided studies indicate that minor non-polar constituents often drive the observed potency, frequently outperforming isolated major compounds. Key isolates such as isoalantolactone and artemisinin derivatives exhibit strong activity via induction of apoptosis, cell-cycle arrest, and ferroptosis, together with inhibition of oncogenic pathways (PI3K/Akt, STAT3, NF-κB, MMP-2/9). In vivo xenograft and chemically induced tumour models confirm tumour regression for several preparations. However, critical methodological shortcomings persist, including the declining use of positive controls and insufficient standardisation. No clinical trials on cancer patients have yet been conducted on herbal preparations of Artemisia. The genus Artemisia therefore represents a valuable reservoir of lead compounds, but future research must prioritise rigorous bioassay-guided fractionation and progression of the most promising candidates into advanced preclinical and clinical studies.

Zitieren

APA

Loots, E., & Kooy, F. V. D. (2026). In vitro and in vivo anticancer potential of Artemisia species: Current evidence and translational challenges. PhytoPharm: International Journal of Phytomedicine and Pharmacology, 1(1), 100005. https://doi.org/10.67623/78jr1f43

Vancouver

Loots E, Kooy FVD. In vitro and in vivo anticancer potential of Artemisia species: Current evidence and translational challenges. PhytoPharm: International Journal of Phytomedicine and Pharmacology. 2026;1(1):100005. doi:10.67623/78jr1f43

BibTeX
@article{Loots2026,
  author = {Loots, Erwin and Kooy, Frank Van der},
  title = {In vitro and in vivo anticancer potential of Artemisia species: Current evidence and translational challenges},
  journal = {PhytoPharm: International Journal of Phytomedicine and Pharmacology},
  year = {2026},
  volume = {1},
  number = {1},
  pages = {100005},
  doi = {10.67623/78jr1f43}
}
Kostenlos starten →